DDAH1 and prostate cancer: Treatment with DD1E5 inhibited proliferation, migration and invasion of prostate cancer cell lines LNCaP and PC3, but was also able to attenuate proliferation of cells stably overexpressing DDAH1; this was accompanied by decreased DDAH1 enzymatic activity, increased ADMA concentration and decreased NO synthesis.